GlassScriptPhysician profile
James M Williams
NPI 1376582031
$359,801.40
in general payments reported to CMS, 2019-2025
16 companies · $13.60 in 2025
The $13.60 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $22K · 2021: $68K · 2022: $191K · 2023: $32K · 2024: $265 · 2025: $13.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $3,164 · Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,200.00 |
| Travel and Lodging | $3,163.87 |
| Food and Beverage | $824.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $153,083.87 | 2019-2024 | Andexxa |
| Janssen Pharmaceuticals, INC | $102,093.11 | 2019-2023 | Xarelto |
| Alexion Pharmaceuticals, INC. | $69,966.44 | 2021-2023 | Andexxa |
| Eagle Pharmaceuticals, INC. | $10,753.12 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $8,622.46 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,366.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,817.02 | 2019-2022 | |
| Instrumentation Laboratory Company | $800.00 | 2021 | |
| Btg International INC. | $778.89 | 2019-2025 | Aurlumyn |
| Quidel Corporation | $200.00 | 2020 | |
| Abbott Laboratories | $143.69 | 2024 | Proclaim, Octrode |
| Merz North America, INC. | $72.56 | 2023 | |
| Fisher Scientific Company L.L.C. | $70.42 | 2019 | |
| Janssen Scientific Affairs, LLC | $19.22 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $13.98 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.